New Agents for Treatment of Dyslipidemia

Vinaya Simha

Research output: Chapter in Book/Report/Conference proceedingChapter


Diabetes mellitus is associated with elevated risk for atherosclerotic cardiovascular disease (ASCVD), and statin therapy has been shown to reduce this risk. ASCVD is leading cause for morbidity and mortality in patients with type 2 diabetes, and heartening trend of decreasing ASCVD mortality in the overall population is unfortunately not seen in patients with diabetes. This chapter summarizes the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in regulation of circulating cholesterol levels, clinical trials of PCSK9 inhibitors, and their optimal use in clinical practice, followed by a brief discussion on emerging triglyceride-lowering therapies. The net effect of PCSK9 is reduced recycling of low density lipoprotein (LDL) receptor to the hepatocyte membrane and resultant decrease in clearance of circulating LDL particles. The available data clearly show the ability of this class of lipid-lowering drugs to safely and effectively reduce the level of LDL-cholesterol and other atherogenic lipoproteins leading to reduced incidence of major vascular events.

Original languageEnglish (US)
Title of host publicationClinical Dilemmas in Diabetes
Subtitle of host publicationSecond Edition
Number of pages9
ISBN (Electronic)9781119603207
ISBN (Print)9781119603160
StatePublished - Jan 1 2021

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'New Agents for Treatment of Dyslipidemia'. Together they form a unique fingerprint.

Cite this